Clinical and pathological response after neoadjuvant chemotherapy with or without zoledronic acid for patients with HER2-negative large resectable or stage II or III breast cancer

被引：0
|
作者：
Charehbili, A. [1 ]
Van de Ven, S. [1 ]
Liefers, G. J. [1 ]
Smit, V. T. [1 ]
Wasser, M. N. [1 ]
Kranenbarg, E. M. Meershoek-Klein [1 ]
Van Leeuwen-Stok, A. E. [2 ]
Van de Velde, C. J. H. [1 ]
Nortier, J. W. R. [1 ]
Kroep, J. R. [1 ]
机构：
[1] Leiden Univ, Med Ctr, Leiden, Netherlands
[2] Dutch Breast Canc Trialists Grp BOOG, Leiden, Netherlands
来源：
EUROPEAN JOURNAL OF CANCER | 2013年 / 49卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
1858
引用
收藏
页码：S401 / S401
页数：1
相关论文
共 50 条
  • [1] Survival outcomes of neoadjuvant chemotherapy with zoledronic acid for HER2-negative breast cancer
    Ishikawa, Takashi
    Akazawa, Kouhei
    Hasegawa, Yoshie
    Tanino, Hirokazu
    Horiguchi, Jun
    Miura, Daishu
    Hayashi, Mitsuhiro
    Kohno, Norio
    JOURNAL OF SURGICAL RESEARCH, 2017, 220 : 46 - 51
  • [2] NEOZOTAC: Efficacy results from a phase III randomized trial with neoadjuvant chemotherapy (TAC) with or without zoledronic acid for patients with HER2-negative large resectable or stage II or III breast cancer (BC)-A Dutch Breast Cancer Trialists' Group (BOOG) study
    Charehbili, Ayoub
    van de Ven, Saskia
    Liefers, Gerrit-Jan
    Smit, Vincent T. H. B. M.
    Putter, Hein
    Heijns, Joan Barbara
    van Warmerdam, Laurens
    Kessels, Lonneke
    Dercksen, Wouter
    Pepels, Manon J.
    Maartense, Eduard
    Van Laarhoven, Hanneke W. M.
    Vriens, Birgit
    Wasser, Martin N.
    Hamdy, Neveen A. T.
    Kranenbarg, Elma Meershoek-Klein
    Van Leeuwen-Stok, Elise
    Van De Velde, Cornelis J. H.
    Kroep, Judith R.
    Nortier, J. W. R.
    JOURNAL OF CLINICAL ONCOLOGY, 2013, 31 (15)
  • [3] A prediction model for pathological complete response after neoadjuvant chemotherapy of HER2-negative breast cancer patients
    Haeberle, L.
    Erber, R.
    Gass, P.
    Hein, A.
    Jud, S. M.
    Langemann, H.
    Rauh, C.
    Hack, C. C.
    Schulz-Wendtland, R.
    Hartmann, A.
    Beckmann, M. W.
    Lux, M. P.
    Fasching, P. A.
    ANNALS OF ONCOLOGY, 2018, 29
  • [4] Addition of zoledronic acid to neoadjuvant chemotherapy does not enhance tumor response in patients with HER2-negative stage II/III breast cancer: the NEOZOTAC trial (BOOG 2010-01)
    Charehbili, A.
    van de Ven, S.
    Smit, V. T. H. B. M.
    Meershoek-Klein Kranenbarg, E.
    Hamdy, N. A. T.
    Putter, H.
    Heijns, J. B.
    van Warmerdam, L. J. C.
    Kessels, L.
    Dercksen, M.
    Pepels, M. J.
    Maartense, E.
    van Laarhoven, H. W. M.
    Vriens, B.
    Wasser, M. N.
    van Leeuwen-Stok, A. E.
    Liefers, G. J.
    van de Velde, C. J. H.
    Nortier, J. W. R.
    Kroep, J. R.
    ANNALS OF ONCOLOGY, 2014, 25 (05) : 998 - 1004
  • [5] NEO-ZOTAC: A Phase Ill Randomized Trial with Neoadjuvant Chemotherapy (TAC) with or without Zoledronic Acid for Patients with HER2-Negative Large Resectable or Locally Advanced Breast Cancer.
    van de Ven, S.
    Nortier, J. W. R.
    Liefers, G. J.
    ten Tije, A.
    Kessels, L. W.
    van Laarhoven, H. W. M.
    van Warmerdam, L. J. C.
    Vriens, B.
    van den Bosch, J.
    Kranenbarg, van Meershoek-Klein E.
    van Leeuwen, E.
    Kroep, J. R.
    CANCER RESEARCH, 2011, 71
  • [6] Prediction of pathological complete response after neoadjuvant chemotherapy for HER2-negative breast cancer patients with routine immunohistochemical markers
    Haeberle, Lothar
    Erber, Ramona
    Gass, Paul
    Hein, Alexander
    Niklos, Melitta
    Volz, Bernhard
    Hack, Carolin C.
    Schulz-Wendtland, Ruediger
    Huebner, Hanna
    Goossens, Chloe
    Christgen, Matthias
    Doerk, Thilo
    Park-Simon, Tjoung-Won
    Schneeweiss, Andreas
    Untch, Michael
    Nekljudova, Valentina
    Loibl, Sibylle
    Hartmann, Arndt
    Beckmann, Matthias W.
    Fasching, Peter A.
    BREAST CANCER RESEARCH, 2025, 27 (01)
  • [7] Neoadjuvant Chemotherapy and Bevacizumab for HER2-Negative Breast Cancer
    von Minckwitz, Gunter
    Eidtmann, Holger
    Rezai, Mahdi
    Fasching, Peter A.
    Tesch, Hans
    Eggemann, Holm
    Schrader, Iris
    Kittel, Kornelia
    Hanusch, Claus
    Kreienberg, Rolf
    Solbach, Christine
    Gerber, Bernd
    Jackisch, Christian
    Kunz, Georg
    Blohmer, Jens-Uwe
    Huober, Jens
    Hauschild, Maik
    Fehm, Tanja
    Mueller, Berit Maria
    Denkert, Carsten
    Loibl, Sibylle
    Nekljudova, Valentina
    Untch, Michael
    NEW ENGLAND JOURNAL OF MEDICINE, 2012, 366 (04): : 299 - 309
  • [8] NEO-ZOTAC: Toxicity data of a phase Ill randomized trial with NEOadjuvant chemotherapy (TAC) with or without ZOledronic acid (ZA) for patients with HER2-negative large resectable or locally advanced breast cancer (BC)
    de Yen, S. van
    Liefers, G-J
    Putter, H.
    van Warmerdam, L. J.
    Kessels, L. W.
    Dercksen, W.
    Pepels, M. J.
    Maartense, E.
    van Laarhoven, H. W. M.
    Vriens, B.
    Smit, V. T. H. B. M.
    Wasser, M. N. J. M.
    Meershoek-Klein, Kranenbarg E. M.
    van Leeuwen-Stok, E.
    van de Velde, C. J. H.
    Nortier, J. W. R.
    Kroep, J. R.
    CANCER RESEARCH, 2012, 72
  • [9] A randomized controlled trial comparing zoledronic acid plus chemotherapy with chemotherapy alone as a neoadjuvant treatment in patients with HER2-negative primary breast cancer
    Hasegawa, Y.
    Kohno, N.
    Horiguchi, J.
    Miura, D.
    Ishikawa, T.
    Hayashi, M.
    Takao, S.
    Kim, S. J.
    Tanino, H.
    Miyashita, M.
    Konishi, M.
    Shigeoka, Y.
    Yamagami, K.
    Akazawa, K.
    CANCER RESEARCH, 2012, 72
  • [10] Addition of zoledronic acid to neoadjuvant chemotherapy is not beneficial in patients with HER2-negative stage II/III breast cancer: 5-year survival analysis of the NEOZOTAC trial (BOOG 2010-01)
    de Groot, Stefanie
    Pijl, Hanno
    Charehbili, Ayoub
    van de Ven, Saskia
    Smit, Vincent T. H. B. M.
    Meershoek-Klein Kranenbarg, Elma
    Heijns, Joan B.
    van Warmerdam, Laurence J. C.
    Kessels, Lonneke W.
    Dercksen, M. Wouter
    Pepels, Manon J. A. E.
    van Laarhoven, Hanneke W. M.
    Vriens, Birgit E. P. J.
    Putter, Hein
    Fiocco, Marta
    Liefers, Gerrit-Jan
    van der Hoeven, Jacobus J. M.
    Nortier, Johan W. R.
    Kroep, Judith R.
    BREAST CANCER RESEARCH, 2019, 21 (01)
12345